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Though extensively characterized clinically, the causes of autism spectrum disorder (ASD)
remain a mystery. ASD is known to have a strong genetic basis, but it is genetically
very heterogeneous. Recent studies have estimated that de novo disruptive mutations
in hundreds of genes may contribute to ASD. However, it is unclear how it is possible for
mutations in so many different genes to contribute to ASD. Recent findings suggest that
many of the mutations disrupt genes involved in transcription regulation that are expressed
prenatally in the developing brain. De novo disruptive mutations are also more frequent
in girls with ASD, despite the fact that ASD is more prevalent in boys. In this paper, we
hypothesize that loss of robustness may contribute to ASD. Loss of phenotypic robustness
may be caused by mutations that disrupt capacitors that operate in the developing brain.
This may lead to the release of cryptic genetic variation that contributes to ASD. Reduced
robustness is consistent with the observed variability in expressivity and incomplete
penetrance. It is also consistent with the hypothesis that the development of the female
brain is more robust, and it may explain the higher rate and severity of disruptive de novo
mutations in girls with ASD.
Keywords: autism spectrum disorder, de novo mutation, chromatin regulators, phenotypic robustness, common
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INTRODUCTION
The genetic architecture of ASD is very complex and hard to
dissect. Recently, there have been several breakthroughs in our
understanding of this heterogeneous disease, including increased
appreciation of the importance of de novo mutations (Sebat
et al., 2007). We now know that ASD can be triggered by dif-
ferent types of genetic variations in many different genes, a phe-
nomenon termed non-allelic genetic heterogeneity. It is estimated
that mutations that are likely to disrupt gene function (such as
nonsense, splice site and frameshift mutations) in hundreds of
different genes may contribute to ASD (Iossifov et al., 2012; Neale
et al., 2012). The involvement of raremutations was clear from the
finding that ASD is associated with genetic syndromes that show
Mendelian inheritance (Cook et al., 1997; Manning et al., 2004;
Splawski et al., 2004; Abrahams and Geschwind, 2008). In addi-
tion, rare and de novo large chromosomal rearrangements are also
found more frequently in ASD, currently estimated to account for
2–7% of cases (Marshall et al., 2008; Shen et al., 2010).
Recently, with the advent of molecular tools that enable to
study the genome in high resolution and unbiased way, de novo
variations, both copy number variations (CNVs) and single
nucleotide variations (SNVs), have been found to be associated
with ASD, currently estimated to account for 6 and 10% of the
cases, respectively (Sebat et al., 2007; Pinto et al., 2010; Sanders
et al., 2011; Iossifov et al., 2012; Neale et al., 2012; O’Roak et al.,
2012b; Sanders et al., 2012). Based on the rate of de novo SNVs
it has been estimated that hundreds of genes can lead to ASD
when disrupted (Iossifov et al., 2012; Neale et al., 2012; O’Roak
et al., 2012b; Sanders et al., 2012). Consequently, each gene could
account for only a small proportion of cases.
MOLECULAR MECHANISMS AFFECTED BY RARE DE NOVO
MUTATIONS
The current view of the genetic architecture of ASD is that it
is similar to other complex diseases. ASD risk is attributed to
both rare genetic variants and combinations of common variants
that act together with environmental risk factors (Huguet et al.,
2013). It is assumed that people with ASD have a set of genetic
variants that predispose them to abnormal development of spe-
cialized brain structures involved in social information processing
(the “social brain”). Thus, it is puzzling that there is no unifying
pathophysiology in ASD, in addition to the findings of mutations
in many different genes, involved in different functions.
A possible solution to this puzzle would be if shared mech-
anisms between some of those genes could be identified. First
attempts to identify such mechanisms focused on genes within
rare copy-number variations (de novo or inherited) (Pinto et al.,
2010; Gai et al., 2011; Gilman et al., 2011). One such effort found
enrichment in rare deletions for genes involved in neuronal devel-
opment and function, as well as for GTPase/Ras signaling (Pinto
et al., 2010). Other studies found enrichment in CNVs for genes
involved in synaptic transmission (Gai et al., 2011) and synap-
togenesis (Gilman et al., 2011). It is important to note, however,
that enrichment studies in CNVs have several limitations. First,
the power of enrichment analyses based on CNVs is limited by
their large size, which in many cases encompasses a large number
of genes. Furthermore, in such analyses gene size may also be an
important confounding factor, especially when dealing with dis-
orders of the brain (Raychaudhuri et al., 2010). Another approach
was to study genes with single base mutations; including muta-
tions that lead to ASD associated genetic syndromes (Sakai et al.,
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2011; Ben-David and Shifman, 2012). However, many of these
genes have been discovered in studies which were at least partly
hypothesis driven, and used previous knowledge to identify the
causal gene in large inherited chromosomal aberrations or segre-
gating loci in families with ASD.
The advent of next generation sequencing, and with it the
recent sequencing of four large ASD cohorts of families for de
novo exonic mutations (Iossifov et al., 2012; Neale et al., 2012;
O’Roak et al., 2012b; Sanders et al., 2012), has provided an
unprecedented sample of de novo disruptions which have been
discovered in an unbiased genome-wide manner, each affect-
ing a specific gene. When combining the mutations found in
these cohorts and performing a functional enrichment analy-
sis, an enrichment was found for genes involved in transcription
regulation, and in particular chromatin regulators that con-
trol chromatin structure and function (Table 1) (Ben-David and
Shifman, 2013). This enrichment is apparent when concentrat-
ing on genes with mutations highly likely to be functional—
nonsense, frame shift or splice site mutations (Ben-David and
Shifman, 2013). When looking at the temporal expression pat-
tern of these genes during brain development, they were found
to be strongly expressed prenatally, with much lower expression
after birth (Ben-David and Shifman, 2013). The specificity of the
enrichment of transcription regulators to ASD was demonstrated
by comparing the distribution of mutations between cases and a
large set of controls, and to unaffected siblings. Furthermore, by
comparing the distribution of disruptive vs. silent mutations in
the same subjects it was shown that the enrichment of chromatin
regulators is unlikely to be a result of detection or mutation bias
(Ben-David and Shifman, 2013). Still it is not clear how disrup-
tive mutations in chromatin regulators and other genes involved
in regulation of transcription link to ASD. We suggest below that
mutation in chromatin regulators causes loss of the robustness
of brain development that together with other ASD specific risk
factors may lead to ASD.
DECREASED ROBUSTNESS IN ASD
Phenotypic robustness is the insensitivity of the phenotype to
genetic or environmental perturbations. An equivalent concept
is developmental stability, which is defined as the ability of the
individual to produce a robust phenotype even if faced with
genetic and environmental perturbations during development.
A further related term is canalization, which refers to the selec-
tion during evolution for more stable phenotypes, or in other
words, adaptive robustness (Gibson and Wagner, 2000). In the
following, we will use the term phenotypic robustness without the
distinction between adaptive and intrinsic forms of robustness
(Gibson and Wagner, 2000). Loss of phenotypic robustness has
been recently proposed to explain the missing heritability in com-
plex disease (Gibson, 2009; McGrath et al., 2011; Queitsch et al.,
2012). Based on this proposal, the degree of robustness varies
between individuals and it influences the probability of develop-
ing a disease or disorder. It was also argued that findings in ASD
and schizophrenia may be consistent with decreased robustness,
a phenomenon termed decanalization (Woolf, 1997; McGrath
et al., 2011; Queitsch et al., 2012). Furthermore, it was speculated
that brain structures (such as the neocortex) that have undergone
profound evolution in the recent lineage leading to humans, may
be more vulnerable to loss of robustness because there has been
insufficient time to evolve sufficient buffering capacity (McGrath
et al., 2011). The brain may be also more vulnerable than other
organs, because it is a complex organ that develops later in life
andmainly composed of terminally differentiated cells. In the first
years of life, the brain may be particularly sensitive to reduced
robustness because the social development depends on signals
from the environment.
The development of the brain is generally robust, so it may
seem surprising that de novo mutations in the heterozygote
state contribute to ASD and other neurodevelopmental disorders.
Many genes can be inhibited in mice without producing a pheno-
type. Moreover, heterozygous knockout (KO) mice rarely show
Table 1 | Chromatin regulators associated with autism spectrum disorders*.
Gene symbol Chromosomal location Support for autism Evidence of support
ADNP 20q13.13 Rare single gene mutations O’Roak et al., 2012a,b
ARID1B 6q25.1 Rare single gene mutations Halgren et al., 2011; Nord et al., 2011
CHD7 8q12.2 Syndromic—CHARGE syndrome Vissers et al., 2004; O’Roak et al., 2012b
CHD8 14q11.2 Rare single gene mutations O’Roak et al., 2012a,b; Talkowski et al., 2012
CREBBP 16p13.3 Syndromic—Rubinstein-Taybi syndrome (RTS) Petrij et al., 1995
HDAC4 2q37.3 Syndromic—brachydactyly mental retardation syndrome Williams et al., 2010a
MBD5 2q23.1 Rare single gene mutations Wagenstaller et al., 2007; Jaillard et al., 2009;
Van Bon et al., 2010; Williams et al., 2010b;
Talkowski et al., 2011, 2012; Hodge et al., 2013
MECP2 Xq28 Syndromic—Rett syndrome Amir et al., 1999
NSD1 5q35 Syndromic—Sotos syndrome Kurotaki et al., 2002
POGZ 1q21.3 Rare single gene mutations Iossifov et al., 2012; Neale et al., 2012
SETD2 3p21.31 Rare single gene mutations O’Roak et al., 2012a,b
SUV420H1 11q13.2 Rare single gene mutations Iossifov et al., 2012; Sanders et al., 2012
*Adapted from SFARI gene database on July 16th 2013, chromatin regulators were taken if they were either associated with syndromic ASD, or had rare mutations
in at least two different individuals.
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a clear phenotype; In fact, in many experiments heterozygous
KO mice are often used as a control for homozygote KO mice.
While neurodevelopmental systems have evolved to be robust,
they may be vulnerable to perturbations in a specific subset of
genes, termed phenotypic capacitors (Rutherford and Lindquist,
1998; Levy and Siegal, 2008). Phenotypic capacitors are genes
that buffer against perturbations and therefore contribute to the
robustness of the phenotype. So, phenotypic capacitors, when
operating normally, may prevent the development of disorders
like ASD even in individuals carrying or exposed to genetic and
environmental risk factors.
The most studied capacitor is Hsp90 (Rutherford and
Lindquist, 1998). Hsp90 was termed “genetic capacitor” because
the reduction in its activity increased phenotypic variation. It was
first suggested that its chaperone activity, that facilitate the correct
folding of proteins with destabilizing mutations, is how Hsp90
can buffer mutations (Tokuriki and Tawfik, 2009). However, more
recent work has suggested that Hsp90 prevents phenotypic vari-
ation by suppressing transposon activity (Specchia et al., 2010).
Besides Hsp90, yeast and worm studies strongly implicate chro-
matin regulators to be phenotypic capacitors (Lehner et al., 2006;
Levy and Siegal, 2008; Tirosh et al., 2010). In yeast, more than
300 genes are known to be important for robustness. Very similar
to the type of genes implicated in ASD, the phenotypic capaci-
tors in yeast tend to be highly connected regulatory genes, many
of which are involved in transcription and chromatin regulation
(Levy and Siegal, 2008). Amajor source of variation during devel-
opment is stochastic fluctuations in gene expression (McAdams
and Arkin, 1997). Gene expression shows significant variation,
even between genetically identical cells (Lehner, 2008). In this
setting, chromatin regulators and other transcription factors are
likely critical to the ability of a cell to buffer the fluctuations in
gene expression against cryptic genetic variations (Tirosh et al.,
2010). Cryptic genetic variations are hidden genetic variations
that do not affect the trait in a given genetic background or envi-
ronmental condition, but may be expressed after environmental,
genetic, or epigenetic perturbations (Gibson and Dworkin, 2004).
The chromatin regulators that were found to be disrupted by
de novo mutations in ASD may be involved in multiple cellular
processes, such as regulation of transcription, cell cycle regula-
tion, genomic stability, and DNA damage repair. Still it is not clear
how mutations in chromatin regulators lead to ASD. While col-
lectively de novo mutations in chromatin regulators account for a
small proportion of cases, understanding how they operate may
shed light on the biological mechanisms of ASD. Following the
models of loss of robustness, we suggest that mutations that affect
chromatin regulators may lead to ASD because they are “global
regulators,” namely they are genes that are placed at the very top of
a regulatory hierarchy. Chromatin regulators interact with many
genes and pathways, and so perturbation in them can affect mul-
tiple target genes simultaneously. Furthermore, we propose that
these genes may also act as phenotypic capacitors, protecting the
developmental processes by buffering genetic and environmen-
tal perturbations. Similarly, other regulators (e.g., transcription
factors and genes involved in translation regulation) may be
associated with ASD because their disruption leads to loss of
robustness. New examples for regulators that are involved in ASD
are topoisomerases. One study found that inhibiting topoiso-
merase 1 (TOP1) reduces the expression of large number of very
long genes, which are particularly expressed in the brain (King
et al., 2013). Two other studies provided evidence that Top3β is
an RNA topoisomerase that interacts with the fragile X mental
retardation protein (FMRP) to regulate the expression of multiple
mRNAs that are crucial for neurodevelopment (Stoll et al., 2013;
Xu et al., 2013).
The proposed model is that individuals, in whom the robust-
ness of brain development has been impaired by genetic or
environmental insults, will have an increased risk of developing a
neurodevelopmental disorder (Figure 1). The specific phenotype
will depend on the combination of other genetic and envi-
ronmental factors including stochastic events. According to this
model, individuals with disruptive mutations in regulators, such
as chromatin regulators, will have reduced phenotypic robustness
(or developmental instability) which may lead to a number of dif-
ferent conditions. In fact, some of the genes found to be disrupted
in individuals with ASD were also found in congenital heart dis-
ease (Zaidi et al., 2013). Similarly, we propose that being a male is
a risk factor for different neurodevelopmental disorders because
of reduced phenotypic robustness. Other factors, including the
environment, may as well lead to loss of robustness. Furthermore,
an individual may carry a mutation that decreases robustness but
will have typical development under specific environmental and
genetic conditions, which are more stable. Aside from the genetic
evidence linking chromatin and other regulators to autism, this
model is also attractive as it has the potential to elucidate a large
set of puzzling observations in ASD. We highlight some of the
evidence for this theory and the evidence for the more classical
view in Table 2. We also propose in Table 2 several experiments
that could be used to test the loss of robustness theory and its
connection to chromatin and other regulators in ASD.
REDUCED ROBUSTNESS IN BRAINS OF MALES VS. FEMALES
One finding that remains consistent in ASD research is that boys
are more likely to be diagnosed with autism than girls. The ratio
between males and females is 4:1, but it may increase up to 15:1
for the high functioning end of the spectrum (Wing, 1981). This
means that girls are less likely to develop ASD, but when they
do, they tend to show a more severe phenotype. There are sev-
eral explanations for this major difference in prevalence between
the sexes. From early prenatal development, through adolescence,
males and females have different levels of sex hormones, such as
testosterone and estrogen. These hormones are known to have a
major influence on brain development, structure and function
(Berenbaum and Beltz, 2011). It has been proposed that differ-
ent hormone levels can increase or decrease the risk of developing
ASD (Baron-Cohen et al., 2005).
A different hypothesis that has gained recent support is that
there are unknown factors that “protect” females from ASD
(Werling and Geschwind, 2013). Recent genome-wide studies
showed that on average females with ASD have more de novo
mutations than males, including CNVs and SNVs (Levy et al.,
2011; Iossifov et al., 2012; Neale et al., 2012). For example, in the
exome sequencing study of Iossifov et al. they observe, on aver-
age, twice the number of de novo disruptive mutations in females
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FIGURE 1 | Variation in ASD risk may be linked to phenotypic
robustness. (A) Evidence to show that females are protected against ASD.
ASD is more prevalent in males; however females exhibit a higher rate of
genes disrupted by de novo mutation. On average, family members of
females with ASD have higher autistic trait scores than the family members
of males with ASD. (B) ASD risk may be associated with phenotypic
robustness, and decreased robustness leads to a higher risk of ASD. For this
reason, males are more predisposed to ASD than females, and individuals
with mutations in phenotypic capacitors have the highest risk. (C) ASD is
characterized by genetic heterogeneity, incomplete penetrance and variable
expressivity. Variations in phenotypic robustness may explain some of the
genetic complexity in ASD. (D) A model of how rare and common variations
cause different neurodevelopmental disorders. A genetic loss of robustness
(decanalization) is caused by mutation in regulators that act as capacitors,
followed by an abnormal development of the brain. Common variations direct
the abnormal development toward a specific trajectory (a specific disorder).
relative to males with ASD (9 in 29 females [31%] vs. 50 in 314
males [16%]). In addition, de novo CNVs in females were larger
and included significantly more genes than CNVs in males (Levy
et al., 2011). A recent study addressed this hypothesis directly
by examining dizygotic twin pairs, comparing autistic traits in
siblings of female and male probands that were at the top 90
and 95th percentiles of the distribution of the autistic trait score
(Robinson et al., 2013). They showed that siblings of females with
ASD had higher scores in autistic traits scale than siblings of males
with the disorder. This result, replicated across two nationally-
representative samples, implies that in girls a greater load of
genetic risk factors is required to cause ASD. Although other stud-
ies did not find the same effect (Ozonoff et al., 2011), this was the
first study to examine representative community samples with-
out ascertainment bias, and using quantitative measurements that
may be more sensitive.
The female protection theory fits with the model of loss
of robustness. According to this model, besides the variation
between individuals, there is a difference in the average degree of
robustness of the brain between males and females. Supporting
this suggestion is the higher rate of boys relative to girls in
other neurodevelopmental disorders such as attention-deficit–
hyperactivity disorder (ADHD), dyslexia, specific language
impairment, Tourette Syndrome, and other learning difficulties
(Shaywitz et al., 1990; Kadesjo and Gillberg, 2000; Rutter et al.,
2003; Simon et al., 2009). There are several possible genetic
explanations for the difference in robustness between males
and females. The early genetic hypothesis was that some genes
involved in ASD are located on the X chromosome (Skuse, 2000).
Females inherit two X chromosomes from both parents, while
males inherit only one maternal copy. Consequently, females are
less vulnerable to mutations in genes on the X-chromosome since
they have a second copy that can compensate. The robustness
model generalizes this concept of genetic protection in females,
by stating that females may have a more robust development of
the brain and therefore require larger perturbations to develop
ASD and other neurodevelopmental disorders. Robustness may
lead to lower prevalence, but it also means that females require
a greater genetic insult that may go along with a more severe
phenotype.
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Table 2 | Evidence for the classical view and the loss of robustness theory in ASD.
Classical view Evidence for
classical view
Loss of robustness theory Evidence based on loss of
robustness
Type of genes
disrupted in
ASD
Genes involved in the
formation or function of brain
circuits important for social
cognition and language
Mutations in genes
involved in synaptic
function Krumm
et al., 2014
Mutations in capacitors* Mutations in chromatin regulators
Ben-David and Shifman, 2013;
Krumm et al., 2014
Differences in
means and in
variances of
traits
ASD risk is caused by
changes in mean values for
social traits
Parents from
multiplex families
show intermediate
autism phenotype
characteristics
Bernier et al., 2012
Increase in variation of cognitive
traits in less robust individuals**
Males show more variations in
cognitive and personality traits than
females Hedges and Nowell, 1995;
Borkenau et al., 2013
Variable
expressivity
and
incomplete
penetrance
The genetic modifier
hypothesis: variability in
expressivity and incomplete
penetrance is due to
additional genetic variations
Evidence from
multiple hit model
Leblond et al., 2012
Individuals with loss of
robustness will be at a higher
risk for different diseases***;
Robust individuals will not show
a phenotype even in the
presence of mutations****
Males show higher incidence for all
neurodevelopmental disorders (see
main text). Individuals with ASD are
more likely to have other brain
related disorders Simonoff et al.,
2008; Memari et al., 2012
Additional experiments and predictions that could be used to provide further evidence for the loss of robustness theory:
*Perturbation of regulators associated with ASD will cause increase the degree of variation in gene expression.
**Animal models with mutations in capacitors linked to ASD will show greater phenotypic variation and increase in fluctuating asymmetry.
***Genetic variants leading to loss of robustness will tend to be shared across diagnostic boundaries, more than other type of variants.
****Animal models carrying mutations in capacitors linked to ASD should have less ability to suppress the effects of other introduced mutations.
LOSS OF ROBUSTNESS MAY EXPLAIN VARIABLE EXPRESSIVITY AND
INCOMPLETE PENETRANCE
Genetic findings from recent years show that mutations asso-
ciated with ASD have low specificity (Figure 1C). Not only
are there probably hundreds of genes that may contribute to
ASD, many of the genes that were identified until now have
also been found to be associated with other neuropsychiatric
conditions, including mental retardation, epilepsy, ADHD, and
schizophrenia (Betancur, 2011; Devlin and Scherer, 2012; Kirov
et al., 2013). This phenomenon is known as variable expressivity,
whereby individuals with a certain mutation exhibit differences
in phenotypic expression, such as disease severity or symptoms.
Variable expressivity among different individuals may arise from
individual-specific genetic and environmental factors. It coincides
with the finding that around 70% of the individuals with ASD
also suffer from other psychiatric conditions (Simonoff et al.,
2008; Memari et al., 2012). In fact, the authors cannot state a
single example of a gene that causes only ASD when disrupted.
Furthermore, some of the rare variants associated with ASD were
observed in individuals with normal development, showing that
those variants may not be sufficient to cause ASD (Zhao et al.,
2007; Ben-Shachar et al., 2009; Beunders et al., 2010; Schaaf et al.,
2011; Kirov et al., 2013). The observation that not all people
who carry a mutation develop the disease is termed incomplete
penetrance. A recent study showed that CNVs associated with
ASD or schizophrenia affect cognition in control individuals. The
CNVs were considered to have incomplete penetrance; however,
the results show that the differences between cases and controls
are in fact due to variable expressivity (Stefansson et al., 2014).
One explanation for the variable expressivity and incomplete
penetrance is that other genetic variations may modify the phe-
notype (Schaaf et al., 2011). Evidence for this explanation comes
from mouse models of ASD. In mouse models, it is very com-
mon to observe a large phenotypic variation dependent on the
genetic background. For example, when the FMR1 (the gene for
fragile X syndrome) knockout mouse was crossed with six differ-
ent inbred strains, only one line (B6.D2 F1 hybrid) showed both
social and communication deficits along with repetitive behaviors
(Spencer et al., 2011). This means that there are genetic variations
between the strains that modify the effect of the mutation without
a direct effect on phenotype. In other words, these effects are due
to epistatic interactions (Epistasis is when the phenotypic effect
of one genotype depends on the genotype of other genes).
In ASD, we suggest to attribute the incomplete penetrance to
differences in robustness among individuals. It was demonstrated
in Caenorhabditis elegans that incomplete penetrance is a conse-
quence of stochastic variation in gene expression, which is influ-
enced by chromatin regulators and other capacitors (Raj et al.,
2010; Burga et al., 2011). Individuals in whom brain development
is more robust are expected to show low variation in gene expres-
sion and lower penetrance for mutations (Queitsch et al., 2012).
Furthermore, in robust individuals some of the genetic varia-
tions will be cryptic. In less robust individuals, such as individuals
with mutations in phenotypic capacitors, genetic variations that
were compensated for will be revealed and contribute to the dis-
ease. Different genetic backgrounds, including common and rare
variations, could explain the phenotypic variations observed in
humans with mutations in the same gene.
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COMMON AND RARE GENETIC VARIANTS OPERATE
TOGETHER TO INCREASE THE RISK OF ASD
As with many other common complex diseases, one of the main
hypotheses about the genetic architecture of ASD was that it is
influenced by common variants (Risch and Merikangas, 1996;
Risch et al., 1999). In addition to past studies looking at candidate
genes, genome-wide association studies were performed in recent
years to identify single nucleotide polymorphism (SNPs) associ-
ated with ASD (Ma et al., 2009; Wang et al., 2009; Weiss et al.,
2009; Anney et al., 2010). While some studies were able to iden-
tify SNPs with genome-wide significance (P < 5× 10−8), none
of those were replicated across studies. Until now, the sample size
in GWAS has been modest (487–1558 families), therefore the fail-
ure of those studies could not be used as evidence against the
contribution of common variants to ASD risk. Although efforts
to identify specific SNP associated with ASD have not been very
successful, several studies have shown that common SNPs collec-
tively contribute to ASD (Voineagu et al., 2011; Ben-David and
Shifman, 2012; Klei et al., 2012), estimated to explain 17–40%
of ASD liability (Klei et al., 2012; Lee et al., 2013). The asso-
ciation of rare variants with ASD, on the other hand, has had
a long history of success, as described above. But, do common
and rare variants operate together? A support for a model that
combines rare and common variations in ASD risk comes from a
study that showed that both typse of variants affect that same kind
of neuronal genes (Ben-David and Shifman, 2012). By dividing
the genes in the human genome into functionally related groups,
based on pattern of gene co-expression in the human brain, it
was shown that genetic risk variants are most enriched in a group
of synaptic genes expressed in adulthood, and in another group
that contains genes involved in neurogenesis (genes active both
during development and adulthood). The “synaptic group” was
more enriched with common risk variants, while the “neurogen-
esis group” with rare variants. Whereas the relative contribution
of rare and common variants is now starting to be explored at
the population level, we still know very little about how com-
mon and rare variations at the individual level act together to
cause ASD.
Adaptive robustness can also be achieved through negative
epistatic interactions among alleles of common variants (Gibson,
2009). In the presence of risk alleles, selection that reduces the
additive genetic effects will result in a more robust phenotype,
since the effect of risk alleles is suppressed by other loci. It was
suggested that dramatic changes in the environment, such as the
ones that accrued inmodern times in human urban societies, may
result in changes in the epistatic interactions among alleles and
reduced robustness (decanalization) (Gibson, 2009). This may
explain the increase in incidence for different common diseases,
including ASD.
As stated above, loss of robustness may increase the risk of
neurodevelopmental disorders, but the specific phenotype may
be modified by common genetic variations (Figure 1D). Thus,
based on this model, genetic variation associated with ASD could
be divided to two types: (1) genetic variation, mainly rare muta-
tions, that reduce the phenotypic robustness of the brain, and (2)
genetic variation, such as common variants, that influence brain
functions involved specifically with social cognition. These latter
variations are cryptic, since they are exposed only in individuals
with loss of robustness. The genetic evidence for such a model
comes from the low specificity of rare mutations, the disruption
of genes that could be considered as master regulators in several
diseases, and the high specificity of common variations to ASD.
The enrichment of genes involved in transcription regulation was
found in ASD, schizophrenia and other neurodevelopmental dis-
orders (Najmabadi et al., 2011; Ben-David and Shifman, 2013;
Gulsuner et al., 2013), suggesting that loss of robustness might
be a more general cause of neurodevelopmental disorders. Hence,
a single rare mutation may be associated with different disorders.
In contrast, there is a very modest or non-significant genetic cor-
relation between ASD and other psychiatric disorders, based on
polygenic risk scores calculated from common variations (Cross-
Disorder Group of the Psychiatric Genomics Consortium, 2013;
Lee et al., 2013).While larger GWAS in ASD are needed to validate
the low correlation, the current findings suggest that common
variations may contribute to the specific phenotypes of ASD in
individuals with rare mutations.
SUMMARY
The classical genetic view of ASD and many other neuropsychi-
atric disorders is focused on genes that code for neural compo-
nents that are essential for brain function. In the field of ASD, a
great deal of research was focused on genes and proteins that are
expressed in the adult brain and function at the synapse, or are
regulated by neuronal activity (Zoghbi, 2003). The notion is that
ASD is caused by mutations that interfere with brain regions or
functions that are involved in the, so called, “social brain.” The
recent developments of new techniques, allowing us to examine
the autism genome in a genome-wide, unbiased manner, have
brought to light another class of genes as associated with ASD
risk. These genes are chromatin regulators, which are active dur-
ing brain development. Based on this finding, and together with
the observation of variable expressivity of mutations and the
recent evidence for a female protective effect, we propose a unify-
ing framework that connects phenotypic robustness theories with
ASD risk (Figure 1). The implication of this theory, if proved true,
is that the prevalence of ASD and other neurodevelopmental dis-
orders may be associated with environmental factors that decrease
robustness.
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